Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051009 | 0.95 | HPGD (0.51) | HPGDSMN1; SMN2HTTALDH1A1NPC1 | |
| SCHEMBL3670854 | 0.95 | HPGD (0.51) | HPGDSMN1; SMN2HTTALDH1A1NPC1 | |
| SCHEMBL30508572 | 0.94 | HPGD (0.50) | HPGDSMN1; SMN2HTTALDH1A1NPC1 | |
| SCHEMBL13225862 | 0.92 | HPGD (0.55) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29380577 | 0.92 | HPGD (0.57) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL155342 | 0.92 | HPGD (0.57) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL19444563 | 0.91 | HPGD (0.56) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL18519252 | 0.90 | HPGD (0.53) | HPGDSMN1; SMN2HTTALDH1A1NPC1 | |
| SCHEMBL9679353 | 0.89 | HPGD (0.46) | HPGDSMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL20648152 | 0.89 | HPGD (0.52) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019755-A | Nanopore | 牛津纳米孔科技公开有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-118011004-A | Method for characterizing target polypeptides using nanopores | 牛津纳米孔科技公开有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117940557-A | Method for preparing modified tumor-infiltrating lymphocytes and application of modified tumor-infiltrating lymphocytes in adoptive cell therapy | 艾欧凡斯生物治疗公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117279506-A | Tumor storage and cell culture compositions | 艾欧凡斯生物治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023018743-A1 | PH-RESPONSIVE NANOPARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-115004030-A | Method | 牛津纳米孔科技公开有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114945679-A | Method for double-strand sequencing | 牛津纳米孔科技公开有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114761799-A | Methods of characterizing target polypeptides using nanopores | 牛津纳米孔科技公开有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| CN-111225958-A | Conductive antifouling coating composition | 哈佛大学校长及研究员协会 | 2020-06-02 | — | — | CN | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170252453-A9 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | ANYGEN CO., LTD. (KR) | 2017-09-07 | — | — | US | disclosed |
| US-20140256623-A1 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | ANYGEN CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| EP-2580326-A1 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION | Antisense Pharma GmbH (DE) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | HPGD 2439/4885SMN1; SMN2 4460/4885HTT 4166/4885 |
| US-20140256623-A1 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | SI, PIGS, MUC1 | HPGD 1283/4885SMN1; SMN2 3280/4885HTT 3733/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | HPGD 2255/4885SMN1; SMN2 4505/4885HTT 4090/4885 |
| US-20170252453-A9 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | SI, PIGS, MUC1 | HPGD 1283/4885SMN1; SMN2 3280/4885HTT 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.